Endocrine Abstracts

Introduction: The PAOLA study in patients with inadequately-controlled acromegaly (n=198) demonstrated superior efficacy of pasireotide long-acting release (LAR; 40 mg/60 mg) in biochemical control (GH <2.5 μg/l and normalized IGF-1) vs continued treatment with octreotide LAR 30 mg/lanreotide Autogel 120 mg (15.4% and 20.0% vs 0%). Here we report preliminary data from the extension phase of PAOLA at wk28.Methods: Pasireotide-LAR (40 mg/...

Background: Some patients with acromegaly do not achieve biochemical control despite receiving maximum-approved doses of currently available somatostatin analogues. This 24-week, randomized study assessed the multireceptor-targeted somatostatin analogue pasireotide LAR vs octreotide LAR/lanreotide Autogel in patients with inadequately controlled acromegaly.Methods: Eligible patients: ≥18 years with mean GH levels ≥2.5 μg/l and IGF1 level...

Background: There is significant interest in how the use of different treatment regimens (e.g. surgery, medical therapy) impacts the clinical course of Acromegaly. This study has been designed to better understand clinical decision making in the context of various treatment options.Methods: OASIS is an international, observational study in recently diagnosed acromegalic patients. Ethical committee approval was obtained where applicable. Observations incl...

Craniopharyngiomas are rare lesions derived from cell remnants of Rathke’s pouch, usually localized in the sellar and suprasellar areas.Objectives: To analyze clinical, endocrine and histological features in a group of patients from Buenos Aires city. To assess efficacy, number of surgeries and complications after surgery or other treatments.Material and methods: Multicentric, retrospective, transversal study. Adult patients w...